Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-02-28
Recursion Pharmaceuticals, Inc.
Recursion is a clinical-stage biotech using an integrated wet-lab + compute platform (Recursion OS) to discover and develop small-molecule medicines and partnered programs.
ai automation biotech healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From AI discovery story to clinical proof-point machine
The upside case is a credibility step-change: one FDA-credible late-stage path plus better partner value capture could re-rate the business. The risk is that without clinical translation, the platform is priced like a commodity service with dilution.

Analysis

Thesis
By 2031, Recursion can re-rate from “AI discovery optionality” to a repeatable evidence-to-asset factory if it converts proprietary Data Universe + automated wet-lab throughput into (1) at least one FDA-credible late-stage path and (2) higher-value, more standardized partner deliverables priced to decision endpoints rather than effort.
Last Economy Alignment
Cheaper compute and better models amplify Recursion’s closed-loop advantage (owned data + automated experiments), but value capture is still gated by slow clinical proof and partner willingness to pay for differentiated, verified decisions (not generic AI tooling).
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
6.2x (from 5 most recent analyses)
Reasoning
The non-linear upside is a step-change in credibility: one program moving onto a clear, efficient pivotal path can shift Recursion from a platform narrative to an investable multi-asset biotech. If that happens, partner deal structures can plausibly move toward standardized, decision-oriented deliverables (and downstream economics), which improves durability versus “AI tools to zero” and funds more shots on goal. The base case is still lumpy, but the payoffs are convex if the clinic validates the loop.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The binding risk is validation: without repeatable human efficacy/safety evidence and an FDA-credible pathway, the platform won’t earn durable economics. The second risk is financing: maintaining wet-lab + compute while running multiple trials can force dilution unless partner cash or a commercial launch arrives. Third is moat erosion: if discovery becomes more standardized and partners in-source, Recursion’s collaboration value capture can compress.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.44
They own a large proprietary biology dataset and automated labs that turn compute into new experiments, creating a learning flywheel as AI gets cheaper. If trials don’t prove the outputs work in humans, the platform gets treated like a replaceable vendor and funding becomes the constraint.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.00
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case